Produced by Araxis Merge on 7/9/2017 11:01:41 PM Eastern Daylight Time. See www.araxis.com for information about Merge. This report uses XHTML and CSS2, and is best viewed with a modern standards-compliant browser. For optimum results when printing this report, use landscape orientation and enable printing of background images and colours in your browser.
# | Location | File | Last Modified |
---|---|---|---|
1 | PPS_N_3.0_Iter2_Build_360.zip\Unredacted\PS_PPS_ui\src\test\resources\messages | generalDoseCheckResponse.xml | Fri Jun 30 19:05:24 2017 UTC |
2 | PPS_N_3.0_Iter2_Build_360.zip\Unredacted\PS_PPS_ui\src\test\resources\messages | generalDoseCheckResponse.xml | Sun Jul 2 20:49:52 2017 UTC |
Description | Between Files 1 and 2 |
|
---|---|---|
Text Blocks | Lines | |
Unchanged | 2 | 596 |
Changed | 1 | 2 |
Inserted | 0 | 0 |
Removed | 0 | 0 |
Whitespace | |
---|---|
Character case | Differences in character case are significant |
Line endings | Differences in line endings (CR and LF characters) are ignored |
CR/LF characters | Not shown in the comparison detail |
No regular expressions were active.
1 | <?xml | |
2 | version="1 .0" | |
3 | encoding=" UTF-8" | |
4 | ?> | |
5 | <PEPSRespo nse | |
6 | ||
7 | xsi:schema Location=" gov/va/med /pharmacy/ peps/exter nal/common /preencaps ulation/vo /drug/chec k/response drugCheck SchemaOutp ut.xsd" | |
8 | ||
9 | xmlns:xsi= "http://ww w.w3.org/2 001/XMLSch ema-instan ce" | |
10 | xmlns="gov /va/med/ph armacy/pep s/external /common/pr eencapsula tion/vo/dr ug/check/r esponse" | |
11 | > | |
12 | ||
13 | <Header> | |
14 | ||
15 | <Time | |
16 | value="084 5" | |
17 | /> | |
18 | ||
19 | <MServer | |
20 | namespace= "VISTA" | |
21 | uci="text" | |
22 | ip=" IP " | |
23 | ||
24 | serverName ="Server N ame" | |
25 | stationNum ber="45" | |
26 | /> | |
27 | ||
28 | <MUser | |
29 | userName=" user" | |
30 | duz="88660 079" | |
31 | jobNumber= "1010" | |
32 | /> | |
33 | ||
34 | <PEPSVersi on | |
35 | difIssueDa te="200810 20" | |
36 | difBuildVe rsion="6" | |
37 | difDbVersi on="3.2" | |
38 | /> | |
39 | ||
40 | </Header> | |
41 | ||
42 | <Body> | |
43 | ||
44 | <drugCheck > | |
45 | ||
46 | <drugDoseC hecks> | |
47 | ||
48 | <drugDoseC heck> | |
49 | ||
50 | <message> | |
51 | ||
52 | <drug | |
53 | orderNumbe r="Z;1;Pro spect" | |
54 | ien="344" | |
55 | gcnSeqNo=" 16579" | |
56 | /> | |
57 | ||
58 | <severity> | |
59 | Informatio n | |
60 | </severity > | |
61 | ||
62 | <type> | |
63 | RenalImpai rment | |
64 | </type> | |
65 | ||
66 | <drugName> | |
67 | SIMVASTATI N ORAL TAB LET 40 MG | |
68 | </drugName > | |
69 | ||
70 | <text> | |
71 | Renal func tion is im portant in this drug 's elimina tion. Dosi ng adjustm ent should be consid ered in pa tients wit h an estim ated creat inine clea rance at o r below 10 ML/MIN. | |
72 | </text> | |
73 | ||
74 | </message> | |
75 | ||
76 | <message> | |
77 | ||
78 | <drug | |
79 | orderNumbe r="Z;1;Pro spect" | |
80 | ien="344" | |
81 | gcnSeqNo=" 16579" | |
82 | /> | |
83 | ||
84 | <severity> | |
85 | Informatio n | |
86 | </severity > | |
87 | ||
88 | <type> | |
89 | HepaticImp airment | |
90 | </type> | |
91 | ||
92 | <drugName> | |
93 | SIMVASTATI N ORAL TAB LET 40 MG | |
94 | </drugName > | |
95 | ||
96 | <text> | |
97 | Hepatic fu nction is important in this dr ug's metab olism. Dos ing adjust ment shoul d be consi dered in p atients wi th signifi cant hepat ic impairm ent. | |
98 | </text> | |
99 | ||
100 | </message> | |
101 | ||
102 | <drug | |
103 | orderNumbe r="Z;1;Pro spect" | |
104 | ien="344" | |
105 | gcnSeqNo=" 16579" | |
106 | /> | |
107 | ||
108 | <doseHigh> | |
109 | 80 | |
110 | </doseHigh > | |
111 | ||
112 | <doseHighU nit> | |
113 | MG/DAY | |
114 | </doseHigh Unit> | |
115 | ||
116 | <doseLow> | |
117 | 5 | |
118 | </doseLow> | |
119 | ||
120 | <doseLowUn it> | |
121 | MG/DAY | |
122 | </doseLowU nit> | |
123 | ||
124 | <doseFormH igh> | |
125 | 2 | |
126 | </doseForm High> | |
127 | ||
128 | <doseFormH ighUnit> | |
129 | EA/DAY | |
130 | </doseForm HighUnit> | |
131 | ||
132 | <doseFormL ow> | |
133 | 0.125 | |
134 | </doseForm Low> | |
135 | ||
136 | <doseFormL owUnit> | |
137 | EA/DAY | |
138 | </doseForm LowUnit> | |
139 | ||
140 | <doseRoute Descriptio n> | |
141 | ORAL | |
142 | </doseRout eDescripti on> | |
143 | ||
144 | </drugDose Check> | |
145 | ||
146 | <drugDoseC heck> | |
147 | ||
148 | <message> | |
149 | ||
150 | <drug | |
151 | orderNumbe r="Z;2;Pro spect" | |
152 | ien="113" | |
153 | ||
154 | vuid="7788 99" | |
155 | gcnSeqNo=" 266" | |
156 | /> | |
157 | ||
158 | <severity> | |
159 | Informatio n | |
160 | </severity > | |
161 | ||
162 | <type> | |
163 | HepaticImp airment | |
164 | </type> | |
165 | ||
166 | <drugName> | |
167 | AMIODARONE HCL ORAL TABLET 200 MG | |
168 | </drugName > | |
169 | ||
170 | <text> | |
171 | Hepatic fu nction is important in this dr ug's metab olism. Dos ing adjust ment shoul d be consi dered in p atients wi th signifi cant hepat ic impairm ent. | |
172 | </text> | |
173 | ||
174 | </message> | |
175 | ||
176 | <drug | |
177 | orderNumbe r="Z;2;Pro spect" | |
178 | ien="113" | |
179 | ||
180 | vuid="7788 99" | |
181 | gcnSeqNo=" 266" | |
182 | /> | |
183 | ||
184 | <doseHigh> | |
185 | 400 | |
186 | </doseHigh > | |
187 | ||
188 | <doseHighU nit> | |
189 | MG/DAY | |
190 | </doseHigh Unit> | |
191 | ||
192 | <doseLow> | |
193 | 100 | |
194 | </doseLow> | |
195 | ||
196 | <doseLowUn it> | |
197 | MG/DAY | |
198 | </doseLowU nit> | |
199 | ||
200 | <doseFormH igh> | |
201 | 2 | |
202 | </doseForm High> | |
203 | ||
204 | <doseFormH ighUnit> | |
205 | EA/DAY | |
206 | </doseForm HighUnit> | |
207 | ||
208 | <doseFormL ow> | |
209 | 0.5 | |
210 | </doseForm Low> | |
211 | ||
212 | <doseFormL owUnit> | |
213 | EA/DAY | |
214 | </doseForm LowUnit> | |
215 | ||
216 | <doseRoute Descriptio n> | |
217 | ORAL | |
218 | </doseRout eDescripti on> | |
219 | ||
220 | </drugDose Check> | |
221 | ||
222 | <drugDoseC heck> | |
223 | ||
224 | <message> | |
225 | ||
226 | <drug | |
227 | orderNumbe r="Z;3;Pro spect" | |
228 | ien="455" | |
229 | gcnSeqNo=" 25485" | |
230 | /> | |
231 | ||
232 | <severity> | |
233 | Informatio n | |
234 | </severity > | |
235 | ||
236 | <type> | |
237 | HepaticImp airment | |
238 | </type> | |
239 | ||
240 | <drugName> | |
241 | INDINAVIR SULFATE OR AL CAPSULE 400 MG | |
242 | </drugName > | |
243 | ||
244 | <text> | |
245 | Hepatic fu nction is important in this dr ug's metab olism. Dos ing adjust ment shoul d be consi dered in p atients wi th signifi cant hepat ic impairm ent. | |
246 | </text> | |
247 | ||
248 | </message> | |
249 | ||
250 | <drug | |
251 | orderNumbe r="Z;3;Pro spect" | |
252 | ien="455" | |
253 | gcnSeqNo=" 25485" | |
254 | /> | |
255 | ||
256 | <doseHigh> | |
257 | 2400 | |
258 | </doseHigh > | |
259 | ||
260 | <doseHighU nit> | |
261 | MG/DAY | |
262 | </doseHigh Unit> | |
263 | ||
264 | <doseLow> | |
265 | 800 | |
266 | </doseLow> | |
267 | ||
268 | <doseLowUn it> | |
269 | MG/DAY | |
270 | </doseLowU nit> | |
271 | ||
272 | <doseFormH igh> | |
273 | 6 | |
274 | </doseForm High> | |
275 | ||
276 | <doseFormH ighUnit> | |
277 | EA/DAY | |
278 | </doseForm HighUnit> | |
279 | ||
280 | <doseFormL ow> | |
281 | 2 | |
282 | </doseForm Low> | |
283 | ||
284 | <doseFormL owUnit> | |
285 | EA/DAY | |
286 | </doseForm LowUnit> | |
287 | ||
288 | <doseRoute Descriptio n> | |
289 | ORAL | |
290 | </doseRout eDescripti on> | |
291 | ||
292 | </drugDose Check> | |
293 | ||
294 | </drugDose Checks> | |
295 | ||
296 | </drugChec k> | |
297 | ||
298 | </Body> | |
299 | </PEPSResp onse> |
Araxis Merge (but not the data content of this report) is Copyright © 1993-2016 Araxis Ltd (www.araxis.com). All rights reserved.